Dr. Bishoy M. Faltas· @FaltasLab · X·· 22 hours agoScore70
Body
Congratulations @tompowles1 and team! EVD #VOLGA #ESMO26
0 likes · 0 reposts · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgPresented at #ESMO26: In patients with muscle-invasive bladder cancer, event-free survival at 24 months was 63.5% with perioperative durvalumab plus neoadjuvant enfortumab vedotin as compared with 45.1% with surgery alone. Full phase 3 VOLGA trial results: https://nej.md/4z7dQFm @myESMO在 X 查看被引用的帖子
Source: Dr. Bishoy M. Faltas · x.com